Dr. Takis Athanasopoulos GSK, UK

Dr. Athanasopoulos is Director & Head of Patient Operations in Product Development & Supply (PD&S), Cell & Gene Therapy (CGT), Medicinal Science & Technology (MST) platform of GSK, Stevenage, UK. Prior to joining PD&S, Dr. Athanasopoulos acted as Director and Head of Transgene Delivery and Vector & Transgene Units, as... read morepart of Cell & Gene Therapy Discovery Research (CGTDR), GSK. Before joining GSK, Dr. Athanasopoulos was a Lecturer in Molecular Biotechnology at the University of Wolverhampton (September 2011-2016), Founder and CEO of Gene & Cell Ltd. and Academic Visitor/Research Consultant for the Gene Therapy Group at Royal Holloway University of London.

For 5 years, before joining the Faculty of Science and Engineering at UoW Dr Athanasopoulos has been a member of the Collaboration for AIDS Vaccine Discovery (CAVD) (www.cavd.org) - an international network of scientists and experts dedicated to designing a variety of novel HIV vaccine candidates and advancing the most promising ones to clinical trials. Dr Athanasopoulos has worked previously as a research staff scientist/PDRA in the School of Biological Sciences at Royal Holloway, University of London (RHUL) (www.rhul.ac.uk). He has also worked on collaborative projects with scientists/clinicians at Royal Free Hospital/UCL and Imperial College London (ICL) and he has been previously funded by the State Scholarship Foundation SF/IKY (Greece), Muscular Dystrophy Campaign (UK), and by the Collaboration for AIDS Vaccine Discovery (CAVD) (www.cavd.org) and the Bill & Melinda Gates Foundation (BMGF).